Evidence map›Paper›PMID 40082837›Full record

ArticleBMC cancer2025

Prognostic role of STMN1 expression and neoadjuvant therapy efficacy in breast cancer.

Li Qian, Zhu Cairong, Liao Yongdong, Li Quan, Zhong Haihu, Zhu Xiaofeng, Ye Xuan, Chen Yongcheng, Chen Kai, Lu Guanming and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Identification ofMolecular medicine reports · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Li Qian *Thyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510655, China.
Zhu Cairong *Thyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510655, China.
Liao Yongdong *Thyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510655, China.
Li QuanThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510655, China.
Zhong HaihuThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510655, China.
Zhu XiaofengThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510655, China.
Ye XuanThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510655, China.
Chen YongchengDepartment of Breast and Thyroid Surgery, Key Laboratory of Molecular Pathology in Tumors of Guangxi, Affiliated Hospital of Youjiang Medical University for Nationalities, Guangxi, China.
Chen KaiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Lu GuanmingDepartment of Breast and Thyroid Surgery, Key Laboratory of Molecular Pathology in Tumors of Guangxi, Affiliated Hospital of Youjiang Medical University for Nationalities, Guangxi, China.
Li JieThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9# Jinsui Road, Guangzhou, 510655, China. lijie2958@gwcmc.org.

Funding

Guangzhou Municipal Science and Technology Project 2024A04J4987National Natural Science Foundation of China 82172917National Natural Science Foundation of China 82201522National Natural Science Foundation of China 82203122National Natural Science Foundation of China 82271650
6 · The paper itself

Abstract

purposebreast cancer is common and highly malignant, currently, STMN1 was found to be associated with several human malignancies. The purpose of this study is to investigate STMN1 expression in breast cancer and explore its role in disease progression and its interaction with neoadjuvant therapy efficacy.

methodswe analyzed the tissue STMN1 mRNA expression in BC tissue samples from 105 patients received with neoadjuvant therapy using qPCR between 2019 and 2022.

resultsStatistical analysis showed that a high expression of STMN1 before neoadjuvant chemotherapy (NACT) was a trend positively related to non-pCR in the ITT (Intention to Treat) population, while in patients with paclitaxel or docetaxel regimens, before-NACT STMN1 expression was obviously higher in non-pCR (failure to achieve pathologically complete response) patients. Additionally, compared to pCR, high expression of STMN1 after NACT was obviously related to non-pCR. Interestingly, Kaplan-Meier analysis demonstrated that patients with mid-high STMN1 expression before and post-NACT had a poorer PFS to compared to those with low expression.

conclusionsSTMN1 is the potential biomarker of NACT and prognosis for breast cancer.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsNeoadjuvant TherapyStathminAdultAgedChemotherapy, AdjuvantDocetaxelFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMiddle AgedPaclitaxelPrognosisBiomarkers, TumorDocetaxelPaclitaxelStathminSTMN1 protein, humanBreast cancermRNANeoadjuvant therapy efficacyPrognosisSTMN1

Identifiers

PMID40082837
PMCPMC11905611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.